Work

Ex-vivo Lung Perfusion Mediated Delivery of Rituximab to Clear Epstein-Barr Virus in Donor Lungs

Year: 2019
Type: dissertation
Abstract: Posttransplant lymphoproliferative disorder (PTLD) is a serious B-cell malignancy that can arise following solid-organ transplantation. PTLD is especially a risk in transplantations involving an Epstein-Barr virus (EBV)-positive donor and an EBV-negative recipient. In this study we utilize ex-vivo lung perfusion (EVLP), a novel platform for treatment, to administer rituximab to eliminate EBV latently infected B-cells in human donor lungs. We demonstrate that rituximab is effectively delivered using EVLP to B-cells residing in the tissue and lymph nodes of the lungs without inducing adverse effects or acute lung injury. Though the results demonstrate that rituximab does not mediate B-cell or viral depletion during perfusion, we show that the perfused monoclonal antibody can induce B-cell reduction 24 hours post-perfusion in-vitro. Our experiments illustrate the potential of EVLP as a platform to deliver monoclonal antibody therapies to expand the donor pool and make it safer.
Author: Terrance Ku
Language: English
Subfield: Surgery
Field: Medicine
Open Access status: green
OpenAlex ID: W3153466849
Cites: 369
Cited by:
Related to: 9